Edition:
India

Neothetics Inc (NEOT.OQ)

NEOT.OQ on NASDAQ Stock Exchange Capital Market

1.41USD
8 Dec 2017
Change (% chg)

-- (--)
Prev Close
$1.41
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
266,279
52-wk High
$2.60
52-wk Low
$0.30

Chart for

About

Neothetics, Inc. is a clinical-stage specialty pharmaceutical company, which develops therapeutics. The Company focuses on localized fat reduction and body contouring. It focuses on the development of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients. LIPO-202 is a first-in-cla... (more)
No analyst recommendations are available for .

Overall

Beta: --
Market Cap(Mil.): $6.33
Shares Outstanding(Mil.): 13.83
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Neothetics qtrly loss per share ‍$0.13​

* Neothetics provides business update and reports third quarter 2017 financial results

08 Nov 2017

BRIEF-Neothetics Inc and Evofem Biosciences Inc announce merger agreement to create Women’S health company

* Neothetics Inc and Evofem Biosciences, Inc. announce merger agreement to create Women’S health company

17 Oct 2017

BRIEF-Neothetics to pay $1.5 mln‍​‍​ to Evofem Biosciences if deal terminated

* Neothetics says if merger agreement with Evofem Biosciences terminated under specified circumstances, co to pay Evofem termination fee of up to $1.5 mln‍​‍​ Source text for Eikon: Further company coverage:

17 Oct 2017

BRIEF-Neothetics posts Q2 loss per share $0.20

* Neothetics provides business update and reports second quarter 2017 financial results

10 Aug 2017

BRIEF-Neothetics announces review of strategic alternatives

* Neothetics Inc - ‍Intends to streamline its operations in order to preserve its capital and cash resources, including implementing a reduction in workforce​

11 Jul 2017

Earnings vs. Estimates